1例成人腺病毒重症肺炎伴呼吸衰竭患者抗感染治疗用药的合理性分析  

Rationality Analysis on Anti-infective Medication in a Case of Adult Adenovirus Severe Pneumonia with Respiratory Failure

作　　者：万君 吴凤 胡琪 崔洁[1] 伍三兰 帅诗媛 黄怡菲 WAN Jun;WU Feng;HU Qi;CUI Jie;WU San-lan;SHUAI Shi-yuan;HUANG Yi-fei(Department of Pharmacy,Gezhouba Central Hospital of Sinopharm,The No.3 Clinical Medical College,China Three Gorges University,Yichang Hubei 443002,China;Union Hospital of Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]三峡大学第三临床医学院国药葛洲坝中心医院药学部,湖北宜昌443002 [2]华中科技大学同济医学院附属协和医院,武汉430022

出　　处：《抗感染药学》2021年第5期665-671,共7页Anti-infection Pharmacy

摘　　要：目的:分析1例成人腺病毒重症肺炎伴呼吸衰竭患者抗感染治疗用药的合理性。方法:对收治的1例成人腺病毒重症肺炎伴呼吸衰竭患者,经抗菌药物阶梯治疗、抗病毒及免疫调节治疗,分析其抗感染用药的全过程,并评估了其临床疗效与用药的合理性。结果:腺病毒导致重症肺炎合并I型呼吸衰竭患者的病情进展迅速,采用多种抗菌药物及免疫调节剂联用治疗后治愈出院,疗效较为明显。结论:重症肺炎患者在抗感染治疗的同时,应辅以免疫调节治疗,提高了临床疗效。Objective:To analyze the rationality of anti-infective medication in a case of adult severe adenovirus pneumonia with respiratory failure.Methods:A case of adult severe adenovirus pneumonia with respiratory failure was treated with antibacterial de-escalation therapy,antiviral therapy and immunomodulatory therapy.The whole process of anti-infective medication was analyzed,and the clinical efficacy and rationality of medication was evaluated.Results:Severe pneumonia with type I respiratory failure caused by adenovirus developed rapidly and was cured and discharged after combined treatment with a variety of antibacterials and immunomodulators with obvious curative effect.Conclusion:Immune regulation therapy should be supplemented with anti-infection therapy in patients with severe pneumonia,which could improve the clinical efficacy.

关 键 词：腺病毒 重症肺炎 抗感染药物 免疫调节 用药分析 

分 类 号：R969.3[医药卫生—药理学]